Background
Phase 3, multicenter, open-label RCT (PRODIGE 24/CCTG PA.6). 493 patients with resected pancreatic ductal adenocarcinoma (PDAC) who had an R0 or R1 resection and a CA 19-9 level ≤180 U/mL within 3 weeks of randomization. Enrolled at French and Canadian centers. Randomized to 24 weeks of adjuvant modified FOLFIRINOX (mFOLFIRINOX) or gemcitabine. Prior to this trial, gemcitabine monotherapy and ESPAC-4 (gemcitabine + capecitabine) were the adjuvant standards. PRODIGE 24 is the largest OS benefit demonstrated in resected PDAC.
Interventions and follow up
Arm A: Modified FOLFIRINOX: oxaliplatin 85 mg/m² + irinotecan 150 mg/m² (reduced after interim safety review from 180 mg/m²) + leucovorin 400 mg/m² + fluorouracil 2400 mg/m² IV q2w × 12 cycles (24 weeks)
Arm B: Gemcitabine 1000 mg/m² days 1, 8, 15 q28d × 6 cycles (24 weeks)
Primary endpoint: Disease-free survival (DFS)
Median follow-up: 33.6 months
Arm B: Gemcitabine 1000 mg/m² days 1, 8, 15 q28d × 6 cycles (24 weeks)
Primary endpoint: Disease-free survival (DFS)
Median follow-up: 33.6 months
Results
DFS: 21.6 vs 12.8 months, HR 0.58 (95% CI 0.46–0.73), P<.001
DFS at 3 years: 39.7% vs 21.4%
OS: 54.4 vs 35.0 months, HR 0.64 (95% CI 0.48–0.86), P=.003
OS at 3 years: 63.4% vs 48.6%
Metastasis-free survival: 21.4 vs 13.0 months, HR 0.59, P<.001
DFS at 3 years: 39.7% vs 21.4%
OS: 54.4 vs 35.0 months, HR 0.64 (95% CI 0.48–0.86), P=.003
OS at 3 years: 63.4% vs 48.6%
Metastasis-free survival: 21.4 vs 13.0 months, HR 0.59, P<.001
Adverse events
Overall grade ≥3: 75.9% (mFOLFIRINOX) vs 52.9% (gemcitabine); discontinuation for AEs 14.7% vs 10.5%, with more dose reductions and hospitalizations in the mFOLFIRINOX arm.
mFOLFIRINOX grade ≥3: Diarrhea 19%, fatigue 11%, peripheral neuropathy 9%, nausea 8%.
Gemcitabine grade ≥3: Fatigue 10%, anemia 5%, thrombocytopenia 4%.
mFOLFIRINOX grade ≥3: Diarrhea 19%, fatigue 11%, peripheral neuropathy 9%, nausea 8%.
Gemcitabine grade ≥3: Fatigue 10%, anemia 5%, thrombocytopenia 4%.
Conclusions
Modified FOLFIRINOX significantly improved DFS and OS compared to gemcitabine as adjuvant therapy after resection of pancreatic ductal adenocarcinoma, with a ~19-month OS benefit, establishing mFOLFIRINOX as the preferred adjuvant regimen for fit patients.
Key Limitations
Key Limitations: Eligibility required CA 19-9 ≤180 U/mL — excluding patients with elevated tumor markers who have worse prognosis, potentially enriching the benefit estimate. Open-label design with subjective DFS events may introduce bias. mFOLFIRINOX toxicity (75.9% grade ≥3) is substantially higher than gemcitabine, limiting applicability to ECOG 0–1 patients recovering well from major surgery. Irinotecan dose was reduced during the trial (from 180 to 150 mg/m²) after a safety signal. Racial and geographic diversity is limited (predominantly French/Canadian centers). ESPAC-4 (gemcitabine + capecitabine) was not included as a comparator despite also being a standard at the time.
Clinical Context
mFOLFIRINOX is now the preferred adjuvant regimen for patients who are ECOG 0–1 and have recovered from surgery with CA 19-9 normalization, per ASCO and ESMO guidelines. Gemcitabine + capecitabine (ESPAC-4) remains a reasonable option for less-fit patients. Neoadjuvant approaches (PREOPANC, Alliance A021501) have shown comparable efficacy and are being evaluated alongside adjuvant strategies. PARP inhibitors (POLO trial, Golan 2019) are an option for maintenance in gBRCA-mutated metastatic PDAC after platinum-based first-line therapy.
References
References: Conroy T et al, NEJM 2018 (PRODIGE 24 primary)